Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlu… (NCT06658197) | Clinical Trial Compass
RecruitingPhase 3
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
China850 participantsStarted 2025-12-25
Plain-language summary
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age is ≥18 years.
✓. AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes).
✓. Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA).
✓. Prestroke mRS score ≤2.
✓. Informed consent from the patient or legally authorised representative.
Exclusion criteria
✕. Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.) or other related conditions identified by CT.
✕. Contraindication to imaging examinations involving contrast agent injection.
✕. Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3).
✕. History of intracranial hemorrhage.
✕. History of severe head trauma or stroke within the past 3 months.
✕. Intracranial or intraspinal surgery within the past 3 months.